Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Latest from Huntsman Cancer Institute at the University of Utah


Atezolizumab/Cabozantinib Displays Promise in High-Risk mCRPC

October 12, 2021

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.

Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19

June 21, 2021

Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.

Hormonal Agents Improve Survival in mCSPC, but Novel Targets Are Needed For Further Drug Development

January 26, 2021

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

Breast Cancer: Chaired by Christos Vaklavas, MD

January 12, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of breast cancer.